Long-term low-molecular-weight heparin (Fragmin) and/or early revascularization during instability in coronary artery disease (the FRISC II study)

American Journal of Cardiology

Volumn 80, Issue 5 A, 1997, Pages

  Wallentin, Lars ^a,b,c,d   Husted, Steen ^a,b,c,d   Kontny, Frederic ^a,b,c,d   Swahn, Eva ^a,b,c,d  

^a UPPSALA UNIVERSITY   (Sweden)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c AKER UNIVERSITY HOSPITAL   (Norway)

^d LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; DALTEPARIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; LOW MOLECULAR WEIGHT HEPARIN; NITRATE; PLACEBO;

ANGIOCARDIOGRAPHY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DEATH; DOUBLE BLIND PROCEDURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

EID: 0030821157     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00493-1     Document Type: Conference Paper

References (18)

1. Low-molecular-weight heparin during instability in coronary artery disease. Lancet. 347:1996;561-568.
2. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB trial. Thrombolysis in myocardial ischemia. Circulation. 89:1994;1545-1556.
3. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med. 335:1996;775-782.
4. Klein W, Buchwald A, Hillis SE, Monrad S, Sanz G, Turpie AGG, van der Meer J, Olaisson E, Undeland S, Ludwig K. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Circulation. 96:1997;61-68.
5. Wallentin L. Low molecular weight heparins - a valuable tool in the treatment of acute coronary syndromes. Eur Heart J. 17:1996;1470-1476.
6. Cohen M, Demers C, Gurfinkel E. Primary endpoint analysis from the ESSENCE Trial: Enoxaparin vs unfractionated heparin in unstable angina and non-Q wave infarction. Reported at the 69th Scientific Sessions of the American Heart Association, New Orleans, LA, 10-13, November, 1996.
7. PARAGON Investigators. A randomised trial of potent platelet IIb/IIIa antagonism, heparin, or both in patients with unstable angina: the PARAGON Study. Reported at the 69th Scientific Sessions of the American Heart Association, New Orleans, LA, 10-13, November, 1996.
8. Dellborg M, Andersen K. Key factors in the identification of the high-risk patient with unstable coronary artery disease: clinical findings, resting 12-lead electrocardiogram, and continuous electrocardiographic monitoring. Am J Cardiol. 80:((Suppl)):1997;35E-39E.
9. Lindahl B, Andrén B, Ohlsson J, Venge P, Wallentin L. Non-invasive risk stratification in unstable coronary artery disease: exercise test and biochemical markers. Am J Cardiol. 80:((Suppl)):1997;40E-44E.
10. Lindahl B, Venge P, Wallentin L. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. J Am Coll Cardiol. 29:1997;43-48.
11. Flather M, Pogue J, Avezum A, Budaj A, Piegas L, Keltai M, Calvin J, Hunt D, Ceremuzinski L, Varigos J, Yusuf S. Effect of baseline characteristics on outcomes in an international prospective registry of acute myocardial infarction without ST elevation. Circulation. 94:1996;I-196.
12. Parisi AF, Khuri S, Deupree RH, Sharma GV, Scott SM, Luchi RJ. Medical compared with surgical management of unstable angina. 5-Year mortality and morbidity in the Veterans Administration Study. Circulation. 80:1989;1176-1189.
13. Sharma GV, Deupree RH, Khuri SF, Parisi AF, Luchi RJ, Scott SM. Coronary bypass surgery improves survival in high-risk unstable angina. Results of a Veterans Administration Cooperative Study with an 8-year follow-up. Circulation. 84:((suppl)):1991;260-267.
14. Boden WE. VANQWISH Study. Reported at the 46th Annual Scientific Sessions of the American College of Cardiology, Anaheim, CA, 16-19, March, 1997.
15. Serruys PW, de Jaegere P, Kiemeneij F. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 331:1994;489-495.
16. Fischman DL, Leon MD, Baim D. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 331:1994;496-501.
17. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 330:1994;956-961.
18. Klootwijk P, Meij S, Melkert R, Simoons ML. Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE). J Am Coll Cardiol. 29:1997;367A.